Trial Profile

Chinese Post-marketing Clinical Study Project Protocol for Evaluate the Safety of BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary)
Indications Coronary artery disease
Focus Therapeutic Use
Acronyms BIOFLOW-China
Sponsors BIOTRONIK

Most Recent Events

16 Dec 2024 Status changed from recruiting to discontinued because according to the renewal registration certificate requirements issued by the NMPA, this product does not need to collect post-market safety data. .
03 Aug 2023 Planned End Date changed from 15 Jul 2029 to 31 Dec 2029.
03 Aug 2023 Planned primary completion date changed from 15 Jul 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com